A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

August 5, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

May 4, 2023

Conditions
InfluenzaRespiratory Viral Infection
Interventions
DRUG

XC221

200 mg/day, for 5 days

DRUG

Placebo

2 tablets/day, for 5 days

Trial Locations (13)

119571

Unimed-C Jsc, Moscow

150030

"State budgetary institution of health care of the Yaroslavl region Clinical Hospital No. 2", Yaroslavl

194156

"Limited Liability Company Health Energy", Saint Petersburg

194358

"St. Petersburg State Budgetary Healthcare Institution City Polyclinic No. 117", Saint Petersburg

195427

"Saint Petersburg State Budgetary Healthcare Institution City polyclinic No. 112", Saint Petersburg

196143

"Limited Liability Company Research Center Eco-Security", Saint Petersburg

199106

"Saint Petersburg State Budgetary Institution of Healthcare City Pokrovskaya Hospital", Saint Petersburg

199178

"St. Petersburg State Budgetary Healthcare Institution City Polyclinic No. 4", Saint Petersburg

199406

"Limited Liability Company Meili", Saint Petersburg

413116

"State autonomous health care institution Engels City Clinical Hospital No. 1", Engel's

614070

Professors' Clinic LLC., Perm

Unknown

"Medical Diagnostic Center Medexpert, LLC", Engel's

"Medical Clinic Ltd.", Saint Petersburg

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY